



Iowa Department of Human Services

Kim Reynolds
Governor

Adam Gregg
Lt. Governor

Jerry R. Foxhoven
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

November 7, 2018

**Location: Iowa State Capitol Room 116
1007 E. Grand Ave
Des Moines, Iowa, 50319**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) DHS Recommendation Letter – August 2018
 - c) Follow-Up from Previous Meeting(s)
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
 - a) Amerigroup
 - b) United Healthcare Community Plan
6. Public Comment* (See Speaker Conflict of Interest Disclosure Form)
7. ProDUR Edits
 - a) Duplicate Antipsychotics in Adults - Updated
 - b) CNS Stimulants and Atomoxetine Concurrent Therapy ProDUR Edit - Updated
 - c) CNS Stimulants and Atomoxetine Age Edit
8. Prior Authorization
 - a) Annual Review of Prior Authorization Criteria
 - b) Kalydeco (Ivacaftor) – Initial Review
 - c) Orkambi (Lumacaftor/Ivacaftor) – Initial Review
 - d) Hematopoietics/Chronic ITP (Thrombopoietin Receptor Agonists) – Initial Review
 - e) Elagolix (Orilissa) – Initial Review

- f) Oral Constipation Agents – Initial Review
- g) Desmopressin Acetate Nasal Spray (Noctiva) – Initial Review
- h) Multiple Sclerosis Agents – Oral – Second Review
- i) Janus Kinase Inhibitors – Second Review
- j) Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitors – Second Review

9. Miscellaneous

- a) DUR Digest Vol. 31, No. 1 – Second Review
- b) MedWatch
- c) Articles of Interest

Empathy is a poor foundation on which to base legislative medical policy

<https://onlinelibrary.wiley.com/doi/abs/10.1111/bioe.12508>

10. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

**Next Meeting
February 6, 2019**

*****Location to be Determined*****